@FiercePharma: France's drug market to shrink this year. No surprise, given the austerity-related cost cuts. Article | Follow @FiercePharma
> AstraZeneca ($AZN) CEO David Brennan saw his total compensation go up 67% last year to £9.1 million ($14.5 million) in a year when revenue and profit fell. Story
> Amgen's Xgeva has received a draft guidance recommendation from NICE for treatment of some patients whose cancer has spread to their bones. Story
> The FDA has extended the review period for the new inhaled COPD treatment from Forest Laboratories and Almirall. Story
> Sanofi's ($SNY) and Isis Pharmaceuticals ($ISIS) have sent a new drug application to the FDA for Kynamro, for the treatment of the genetic condition homozygous familial hypercholesterolemia (HoFH). Story
Biotech News
@FierceBiotech: Roche readies for approvals of previously snubbed breast cancer drug T-DM1. More | Follow @FierceBiotech
@JohnCFierce: Sunesis snags $25M royalty deal on lead drug. Release | Follow @JohnCFierce
@RyanMFierce: Isis is due $25M if FDA accepts newly submitted NDA for mipomersen. Article | Follow @RyanMFierce
> Provenge critic gaining attention after taking shots at study data. Item
> Merrimack Pharma stumbles out of the IPO gate. More
> PhIII failure blights Shire's effort to crack new market for bowel drug. Article
> FDA panel favors added cardio studies for risky weight drugs. Story
Medical Device News
@FierceMedDev: Europe Weighs Tougher Breast Implant Scrutiny - Bloomberg Businessweek. Story | Follow @FierceMedDev
> After 11 malfunctions, St. Jude pulls Brio DBS device. News
> FDA panel to hear experts, patients on metal hips. Story
> Globus files for estimated $100M IPO. Article
> Roche pressures Illumina with higher, $6.7B offer. More
And Finally... The name of Ali Musa Gilani, son of Pakistan Prime Minister Yousaf Raza Gilani, has surfaced in an investigation there into the unauthorized distribution of the ingredient ephedrine, used to make crystal meth. Story